Company intelligence / Profile preview

Emergent Technologies

Austin, Texas, United Statesemergenttechnologiesinc.com ↗

Ownership: Private
Development stage: Other

Overview

Emergent Technologies identifies and commercializes early-stage biotechnology innovations from universities, forming new companies or licensing technologies. Through its portfolio company Caisson Biotech, it has advanced the HEPtune drug delivery platform into clinical collaborations with healthcare providers and pharmaceutical partners such as Novo Nordisk. The focus is on enabling improved therapeutic performance and safety profiles for existing drugs using novel delivery systems.

Therapeutic areas: Other
Modalities: Drug delivery platform
Industry: Investors

Partnerships

Novo NordiskSeton Healthcare Family / University Medical Center Brackenridge / UT Southwestern Clinical Research Institute in Austin

Beyond the preview

Go deeper on Emergent Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emergent Technologies.

Explore the full profile